Lilly Expects Alimta Advisory Committee Review For Non-Small Cell Lung Cancer sNDA

Lilly expects its supplemental NDA for Alimta in second-line, non-small cell lung cancer will be the subject of an advisory committee meeting this year, Investor Relations Manager Heidi Straub said April 19.

News Source: FDA Advisory Committee | Published: April 20, 2004 | Read Full Story

Contact an Asbestos and Mesothelioma Attorney, Lawyer, Law Firm

Please fill out the form below to contact an attorney. Provide as much information as possible to speed the processing of your inquiry (Only United States residents are eligible).

Contact Information
	*Are required items.
*First Name:
*Last Name:
Email Address:
*Daytime Phone:
Evening Phone:
*Zip Code:
Case Information
Have you, or the person you are contacting us on behalf of, been diagnosed with mesothelioma:
Yes: No:
Date of diagnosis:
*Comments: (Please describe your legal issues and needs.)
Terms
I understand submission of information submission of information for review does not create, is not intended to create, and must not be relied upon as creating, an attorney-client relationship. I understand such a relationship can only be created by the agreement of both the client and the attorney, evidenced by a written retainer agreement that has been signed by client and counter-signed by the attorney. By submitting your expression of interest you are consenting to receive telephone calls from participating law firms even if you are currently on the do-not-call list. *I Agree to these terms: